Scott Bizily - Dec 1, 2022 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Signature
/s/ August J. Moretti, Attorney-in-Fact for Scott Bizily
Stock symbol
FDMT
Transactions as of
Dec 1, 2022
Transactions value $
-$94,406
Form type
4
Date filed
12/5/2022, 04:33 PM
Previous filing
Sep 6, 2022
Next filing
Feb 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FDMT Common Stock Options Exercise $12.2K +1.88K +65.63% $6.49 4.73K Dec 1, 2022 Direct F1, F9
transaction FDMT Common Stock Sale -$8.61K -400 -8.45% $21.52 4.33K Dec 1, 2022 Direct F1, F2
transaction FDMT Common Stock Sale -$22.1K -975 -22.51% $22.71 3.36K Dec 1, 2022 Direct F1, F3
transaction FDMT Common Stock Sale -$9.3K -400 -11.92% $23.25 2.96K Dec 1, 2022 Direct F1, F4
transaction FDMT Common Stock Sale -$2.45K -100 -3.38% $24.49 2.86K Dec 1, 2022 Direct F1
transaction FDMT Common Stock Options Exercise $30.2K +3.75K +131.26% $8.04 6.61K Dec 1, 2022 Direct F1
transaction FDMT Common Stock Sale -$21.8K -1K -15.14% $21.78 5.61K Dec 1, 2022 Direct F1, F5
transaction FDMT Common Stock Sale -$56.2K -2.45K -43.7% $22.93 3.16K Dec 1, 2022 Direct F1, F6
transaction FDMT Common Stock Sale -$4.69K -200 -6.34% $23.44 2.96K Dec 1, 2022 Direct F1
transaction FDMT Common Stock Sale -$2.45K -100 -3.38% $24.49 2.86K Dec 1, 2022 Direct F1
transaction FDMT Common Stock Sale -$9.13K -375 -13.13% $24.35 2.48K Dec 1, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FDMT Stock Option (Right to Buy) Options Exercise $0 -1.88K -7.81% $0.00 22.1K Dec 1, 2022 Common Stock 1.88K $6.49 Direct F7
transaction FDMT Stock Option (Right to Buy) Options Exercise $0 -3.75K -6.25% $0.00 56.3K Dec 1, 2022 Common Stock 3.75K $8.04 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2 The transaction was executed in multiple trades in prices ranging from $20.92 to $21.79, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 The transaction was executed in multiple trades in prices ranging from $22.13 to $23.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4 The transaction was executed in multiple trades in prices ranging from $23.16 to $23.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F5 The transaction was executed in multiple trades in prices ranging from $21.21 to $22.12, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F6 The transaction was executed in multiple trades in prices ranging from $22.39 to $23.36, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F7 The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
F8 The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
F9 Reflects 2,857 shares of the Issuer's common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.